FindTrial
Sign In

Efficacy and safety of growth hormone in the treatment of Prader-Willi syndrome

Efficacy and safety of growth hormone in the treatment of Prader-Willi syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900022809
Enrollment
Unknown
Registered
2019-04-26
Start date
2019-05-01
Completion date
Unknown
Last updated
2019-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prader-Willi syndrome

Interventions

control group:Routine treatment such as rehabilitation
Treated group:treatment with growth hormone

Sponsors

Children's Hospital of Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: From May 2019 to May 2021, Prader-Willi Syndrome was diagnosed by gene diagnosis.

Exclusion criteria

Exclusion criteria: Patients with other diseases.

Design outcomes

Primary

MeasureTime frame
height;weight;hepatic and renal function;Fasting blood glucose;blood fat;thyroid function;Dislocation of hip joint;Scoliosis;IGF-1;Developmental Behavior Scale;—

Countries

China

Contacts

Public ContactZOU Chao-Chun

Children's Hospital of Zhejiang University School of Medicine

zcc14@zju.edu.cn+86 15067123060

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026